A two year observation of the process of applying recombinant IGF-1 to treat short stature in children with primary IGF-1 deficiency -- case reports of 3 patients
Petriczko, Eżbieta.; Wikiera, B.; Horodnicka-Józwa, A.; Marcinkiewicz, K.; Szmit-Domagalska, J.; Kędzia, A.; Durzyńska, J.; Broniarczyk, J.; Gabryelczyk, B.; Noczyńska, A.; Walczak, Mław.
Pediatric Endocrinology, Diabetes and Metabolism 17(4): 233-238
2011
ISSN/ISBN: 2081-237X PMID: 22248785 Document Number: 10664
Growth deficiency is one of the most frequent causes of referral to Endocrinology Outpatient Clinic. IGF-1 (insulin-like growth factor 1) deficiency is one of the rarest causes of short stature. In 2009 in Poland a therapeutic programme was set up for children with severe primary IGF-1 deficiency. The authors present the data of three first polish patients qualified for the rhIGF-1 (recombinant human insulin-like growth factor 1) - mecasermin. The authors conclude that the treatment with rhIGF-1 significantly improves growth velocity in patients with IGF-1 deficiency. During two years of mecasermin treatment no serious side effects were noted.
Document emailed within 1 workday
